Hiremon (Propofol)

Hiremon is indicated for use in adult patients when rapid induction of general anesthesia or procedural sedation is required. It is administered intravenously by qualified healthcare professionals safely.

• Induction of anesthesia for surgeries ranging from minor to major procedures.
• Maintenance of anesthesia during operative procedures when continuous sedation is needed.
• Procedural sedation for diagnostic or therapeutic interventions such as endoscopy or bronchoscopy.
• Rapid sequence induction in emergency airway management.
• Sedation for short, painful procedures in intensive care or emergency settings.

• Propofol acts as a positive allosteric modulator of the γ‑aminobutyric acid type A (GABA_A) receptor. By binding to a distinct site on the receptor complex, it enhances the inhibitory effect of GABA, increasing chloride ion influx and hyperpolarizing neuronal membranes. This potentiation leads to decreased neuronal excitability, producing rapid onset of sedation, hypnosis, and loss of consciousness required for anesthesia.

Adverse reactions to Hiremon may vary in frequency and severity, ranging from transient sensations to potentially life‑threatening events.

Common

• Pain or burning sensation at the injection site.
• Transient hypotension or mild blood pressure drop.
• Brief respiratory depression or reduced breathing effort.
• Nausea or vomiting during emergence from anesthesia.
• Mild dizziness or feeling of lightheadedness.
• Transient confusion or disorientation.
• Transient visual disturbances such as blurred vision.
• Mild headache during recovery.

Serious

• Severe hypotension leading to cardiovascular collapse.
• Cardiac arrhythmias such as ventricular tachycardia.
• Allergic reactions including anaphylaxis.
• Respiratory arrest requiring immediate intervention.
• Seizure activity in susceptible patients.

When using Hiremon, clinicians should observe specific precautions to minimize risks and ensure patient safety during anesthesia or sedation.

• Verify patient fasting status to reduce aspiration risk.
• Assess cardiovascular stability; avoid use in patients with uncontrolled hypotension.
• Conduct a thorough airway evaluation before induction.
• Monitor oxygen saturation, blood pressure, and heart rhythm continuously.
• Adjust dose in elderly or debilitated patients due to altered pharmacokinetics.
• Maintain resuscitation equipment and trained personnel nearby throughout the procedure.
• Avoid concurrent use with other central nervous system depressants unless clinically justified.
• Document all administered doses and infusion rates in the patient’s record.

Hiremon may interact with other medications, influencing its sedative effect or cardiovascular profile. Awareness of these interactions helps guide safe co‑administration.

Avoid

• Concurrent use with other potent intravenous anesthetics (e.g., thiopental, etomidate) due to additive depression of central nervous system activity.
• Co‑administration with high‑dose opioids that may cause profound respiratory depression.
• Use with vasodilators that can exacerbate hypotension, such as nitroglycerin.

Use with caution

• Benzodiazepines or barbiturates, which may enhance sedative effects.
• Anticholinergic agents that can mask signs of hypoxia.
• Drugs affecting GABA metabolism, such as certain anticonvulsants.
• Agents that prolong QT interval, requiring cardiac monitoring.